| pubmed-article:2802265 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2802265 | lifeskim:mentions | umls-concept:C0000768 | lld:lifeskim |
| pubmed-article:2802265 | lifeskim:mentions | umls-concept:C1510446 | lld:lifeskim |
| pubmed-article:2802265 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:2802265 | lifeskim:mentions | umls-concept:C0205470 | lld:lifeskim |
| pubmed-article:2802265 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:2802265 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:2802265 | pubmed:dateCreated | 1989-11-9 | lld:pubmed |
| pubmed-article:2802265 | pubmed:abstractText | When in vivo and in vitro studies of patients with myocardial infarction (MI) were compared with healthy controls there was significantly diminished cutaneous cellular immunity and numbers of T lymphocytes in patients who suffered MI. This study contrasted patients with MI to controls and to patients with other types of cardiovascular disease. There was a significant difference when control patients were compared with those who failed to survive MI for 4 weeks (P less than .001). Patients who died in less than 1 month had 3.6 times less circulating percent T-cells than age-matched controls. A new method is described for categorization of in vitro T-cells in human subjects. If certain patients with low numbers of T-cells following MI die, perhaps this information may serve to alert the physician to intervene and correct the patient's course to recovery. | lld:pubmed |
| pubmed-article:2802265 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2802265 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2802265 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2802265 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2802265 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:2802265 | pubmed:issn | 0003-4738 | lld:pubmed |
| pubmed-article:2802265 | pubmed:author | pubmed-author:KaufmanH SHS | lld:pubmed |
| pubmed-article:2802265 | pubmed:author | pubmed-author:KvitashV IVI | lld:pubmed |
| pubmed-article:2802265 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2802265 | pubmed:volume | 63 | lld:pubmed |
| pubmed-article:2802265 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2802265 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2802265 | pubmed:pagination | 287-90 | lld:pubmed |
| pubmed-article:2802265 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:meshHeading | pubmed-meshheading:2802265-... | lld:pubmed |
| pubmed-article:2802265 | pubmed:year | 1989 | lld:pubmed |
| pubmed-article:2802265 | pubmed:articleTitle | Immunologic abnormalities associated with acute ischemic heart disease (a pilot study). | lld:pubmed |
| pubmed-article:2802265 | pubmed:affiliation | Mount Zion Hospital and Medical Center, San Francisco, California. | lld:pubmed |
| pubmed-article:2802265 | pubmed:publicationType | Journal Article | lld:pubmed |
